DE602006020353D1 - Progesterone Dosierungsanweisung in der Behandlung einer traumatischen Verletzung des Gehirns - Google Patents

Progesterone Dosierungsanweisung in der Behandlung einer traumatischen Verletzung des Gehirns

Info

Publication number
DE602006020353D1
DE602006020353D1 DE602006020353T DE602006020353T DE602006020353D1 DE 602006020353 D1 DE602006020353 D1 DE 602006020353D1 DE 602006020353 T DE602006020353 T DE 602006020353T DE 602006020353 T DE602006020353 T DE 602006020353T DE 602006020353 D1 DE602006020353 D1 DE 602006020353D1
Authority
DE
Germany
Prior art keywords
treatment
brain injury
traumatic brain
nervous system
central nervous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006020353T
Other languages
German (de)
English (en)
Inventor
Stuart W Hoffman
Arthur L Kellerman
Donald G Stein
David W Wright
Douglas W Lowery-North
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emory University
Original Assignee
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University filed Critical Emory University
Publication of DE602006020353D1 publication Critical patent/DE602006020353D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
DE602006020353T 2005-03-24 2006-03-24 Progesterone Dosierungsanweisung in der Behandlung einer traumatischen Verletzung des Gehirns Active DE602006020353D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66472805P 2005-03-24 2005-03-24
US72966305P 2005-10-24 2005-10-24

Publications (1)

Publication Number Publication Date
DE602006020353D1 true DE602006020353D1 (de) 2011-04-07

Family

ID=36987966

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006020353T Active DE602006020353D1 (de) 2005-03-24 2006-03-24 Progesterone Dosierungsanweisung in der Behandlung einer traumatischen Verletzung des Gehirns

Country Status (16)

Country Link
US (4) US20090221544A1 (pt)
EP (5) EP1871382B1 (pt)
JP (5) JP5394059B2 (pt)
AT (2) ATE520404T1 (pt)
AU (2) AU2006226774B2 (pt)
CA (2) CA2602950C (pt)
CY (2) CY1111478T1 (pt)
DE (1) DE602006020353D1 (pt)
DK (2) DK2030622T3 (pt)
ES (2) ES2392454T3 (pt)
HK (3) HK1112579A1 (pt)
HR (2) HRP20110198T1 (pt)
PL (2) PL2030622T3 (pt)
PT (2) PT1868614E (pt)
RS (1) RS52471B (pt)
WO (2) WO2006102644A2 (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006226774B2 (en) 2005-03-24 2010-12-02 Emory University Methods for the treatment of central nervous system injury via a tapered administration of progesterone
US7473687B2 (en) * 2005-03-24 2009-01-06 Emory University Methods for the treatment of a traumatic central nervous system injury
EP2052724A1 (en) 2007-10-26 2009-04-29 sanofi-aventis Use of norgestimate as a selective inhibitor of TRPC3, TRPC6 and TRPC6 and TRPC7 ion channel
US9527881B2 (en) 2008-02-26 2016-12-27 Emory University Steroid analogues for neuroprotection
EP2331571B1 (en) 2008-09-18 2015-08-26 Northwestern University Nmda receptor modulators and uses thereof
US20110306579A1 (en) * 2009-01-30 2011-12-15 Emory University Methods of neuroprotection using neuroprotective steroids and a vitamin d
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
US20110262502A1 (en) * 2010-02-08 2011-10-27 Prairie Pharmaceuticals LLC Pulmonary delivery of 17-hydroxyprogesterone caproate (17-hpc)
ES2773079T3 (es) 2010-02-08 2020-07-09 Shenzhen Evergreen Therapeutics Co Ltd Métodos para el uso de progestágeno como sensibilizador de glucocorticoides
US10987361B2 (en) 2010-02-08 2021-04-27 Shenzhen Evergreen Therapeutics Co., Ltd. Treating auto-immune and auto-inflammatory diseases
US10993879B2 (en) * 2010-02-08 2021-05-04 Shenzhen Evergreen Therapeutics Co., Ltd. Pulmonary delivery of progestogen
TW201138782A (en) 2010-04-26 2011-11-16 Besins Healthcare Lu Sarl Low-oil pharmaceutical emulsion compositions comprising progestogen
MX357761B (es) * 2011-04-27 2018-07-23 Univ Northwestern Métodos para tratar la enfermedad de alzheimer, enfermedad de huntington, autismo u otros trastornos.
WO2013043985A1 (en) 2011-09-23 2013-03-28 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
SG10201606063RA (en) * 2012-01-23 2016-09-29 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
US20130210785A1 (en) 2012-02-15 2013-08-15 Emory University Progesterone analogs and uses related thereto
MX356427B (es) 2012-02-29 2018-05-29 Braun Melsungen Ag Emulsion que contiene hormona.
RU2498826C1 (ru) * 2012-05-14 2013-11-20 Федеральное государственное бюджетное учреждение науки Комплексный научно-исследовательский институт им. Х.И. Ибрагимова Российской академии наук Способ лечения больных с черепно-мозговой травмой
IL304912A (en) 2012-08-21 2023-10-01 Sage Therapeutics Inc Treatment methods for epilepsy and status epilepticus
EP2925327B1 (en) 2012-11-30 2024-01-10 The Regents of The University of California Allopregnanolone for treating, reducing or mitigating symptoms of post-partum depression
SI3514158T1 (sl) 2013-01-29 2023-03-31 Aptinyx Inc. Spirolaktamski modulatorji NMDA-receptorja in njihove uporabe
JP6531042B2 (ja) 2013-01-29 2019-06-12 アプティニックス インコーポレイテッド スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用
EA201591404A1 (ru) 2013-01-29 2016-01-29 Аптиникс Инк. Спиролактамные модуляторы рецептора nmda и их применение
EA201591405A1 (ru) 2013-01-29 2017-05-31 Аптиникс Инк. Спиролактамные модуляторы nmda-рецептора и их применение
KR20150110787A (ko) 2013-01-29 2015-10-02 노렉스, 인크. 스피로-락탐 nmda 수용체 조절인자 및 그의 용도
WO2015023593A1 (en) 2013-08-12 2015-02-19 Emory University Progesterone phosphate analogs and uses related thereto
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
US10231979B2 (en) * 2015-08-07 2019-03-19 Indiana University Research And Technology Corporation Modulation of inflammation using progesterone metabolites
WO2017156103A1 (en) 2016-03-08 2017-09-14 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
PE20190174A1 (es) 2016-05-19 2019-02-01 Aptinyx Inc Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
IL264496B (en) 2016-08-01 2022-09-01 Aptinyx Inc Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
WO2018026798A1 (en) 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam nmda modulators and methods of using same
BR112019001921A2 (pt) 2016-08-01 2019-05-14 Aptinyx Inc. moduladores do receptor nmda de espiro-lactama e seus usos
US10918637B2 (en) 2016-08-01 2021-02-16 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
CA3031537A1 (en) 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
AU2019215058A1 (en) 2018-01-31 2020-09-17 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
EP3918336A1 (en) * 2019-01-31 2021-12-08 University of Geneva Prospective markers in traumatic brain injury (tbi)
JP2022523564A (ja) 2019-03-04 2022-04-25 アイオーカレンツ， インコーポレイテッド 機械学習を使用するデータ圧縮および通信
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy
KR20240144112A (ko) * 2021-12-02 2024-10-02 마블바이옴 인코포레이티드 미주신경 관련 질환, 장애 및 병태를 치료하기 위한 마이크로바이옴 조성물, 성분 또는 대사산물의 방법 및 용도
WO2024059056A1 (en) * 2022-09-12 2024-03-21 Emory University Methods of managing traumatic brain injury

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5217085A (en) 1975-07-30 1977-02-08 Ono Pharmaceut Co Ltd Method of quantitative determination of free fatty acids in serum usin g fatty acid activating enzymes
US4404366A (en) * 1980-05-06 1983-09-13 Miles Laboratories, Inc. Beta-galactosyl-umbelliferone-labeled hapten conjugates
US4369250A (en) 1981-07-31 1983-01-18 Sherwood Medical Industries Inc. Fatty acid determination
US5120723A (en) * 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
USRE35517E (en) * 1987-08-25 1997-05-20 University Of Southern California Method, compositions, and compounds for modulating brain excitability
AU609927B2 (en) 1987-08-25 1991-05-09 Kelvin W. Gee Compositions and methods for alleviating stress, anxiety and seizure activity
US5512429A (en) 1989-09-19 1996-04-30 British Technology Group Limited Assay for enzyme activity
GB9105707D0 (en) 1991-03-18 1991-05-01 Wilton David C Assay
US5114388A (en) * 1991-07-26 1992-05-19 True Fitness Technology, Inc. Stair simulator exerciser with adjustable incline
US5212167A (en) * 1991-09-12 1993-05-18 Trustees Of Boston University Modulation of receptor-mediated ion transport
US5206415A (en) * 1991-12-20 1993-04-27 Washington University Tricyclic steroid analogs
CN1100541C (zh) * 1993-01-19 2003-02-05 恩多研究公司 脱氢表雄酮的治疗用途和传送系统
US5776923A (en) * 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
DE4311870C2 (de) 1993-04-10 1998-07-30 Altramed Holdings Ltd Verwendung eines Anti-Östrigens zur Therapie und Prophylaxe von Demenz-Erkrankungen
WO1995005826A1 (en) * 1993-08-20 1995-03-02 Jackson Meyer B Method for regulating neuropeptide hormone secretion
US5763431A (en) * 1993-08-20 1998-06-09 Jackson; Meyer B. Method for regulating neuropeptide hormone secretion
US5939545A (en) * 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
US5633011A (en) * 1994-08-04 1997-05-27 Alza Corporation Progesterone replacement therapy
FR2727117A1 (fr) * 1994-11-18 1996-05-24 Geffard Michel Utilisation de conjugues de la polylysine pour la preparation de medicaments utiles dans le traitement des maladies neurodegeneratives et des affections degeneratives a caractere autoimmun
US5767117A (en) * 1994-11-18 1998-06-16 The General Hospital Corporation Method for treating vascular headaches
US5837544A (en) * 1995-02-02 1998-11-17 Cell Genesys, Inc. Method of inducing a cell to proliferate using a chimeric receptor comprising janus kinase
DE69634039T2 (de) * 1995-06-06 2005-12-08 Euro-Celtique S.A. Steroidderivate der Androstan- und der Pregnanreihe
HUP9700322A3 (en) * 1995-06-09 2001-03-28 Euro Celtique Sa Formulations and methods for providing prolonged local anesthesia
US5888996A (en) * 1995-07-26 1999-03-30 Trustees Of Boston University Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity
CA2256365A1 (en) 1996-05-22 1997-11-27 Diversified Pharmaceuticals, Inc. Compositions, methods and devices for the transdermal delivery of drugs
US5763492A (en) * 1996-10-01 1998-06-09 Duguesne University Of The Holy Ghost Methods for effecting memory enhancement mediated by non-steroidal sulfatase inhibitors
AU739146B2 (en) 1997-05-02 2001-10-04 Wyeth Pregnan-3-ol-20-ones
US6245757B1 (en) * 1997-10-03 2001-06-12 Research Corporation Technologies, Inc. Use of progestins to treat ischemic event
US6174547B1 (en) * 1999-07-14 2001-01-16 Alza Corporation Dosage form comprising liquid formulation
US6268223B1 (en) 1999-08-27 2001-07-31 Viatech Imagin, Llc Assay for detecting damage to the central nervous system
US20020072509A1 (en) * 2000-10-11 2002-06-13 Stein Donald Gerald Methods for the treatment of a traumatic central nervous system injury
US7473687B2 (en) * 2005-03-24 2009-01-06 Emory University Methods for the treatment of a traumatic central nervous system injury
AU2006226774B2 (en) * 2005-03-24 2010-12-02 Emory University Methods for the treatment of central nervous system injury via a tapered administration of progesterone

Also Published As

Publication number Publication date
EP1868614B1 (en) 2012-08-08
US20120289491A1 (en) 2012-11-15
CA2601715A1 (en) 2006-09-28
JP5394059B2 (ja) 2014-01-22
JP5295755B2 (ja) 2013-09-18
JP2008534512A (ja) 2008-08-28
WO2006102644A9 (en) 2006-11-23
AU2006226811A1 (en) 2006-09-28
ES2392454T3 (es) 2012-12-10
WO2006102596A3 (en) 2007-01-18
CY1111478T1 (el) 2015-08-05
WO2006102644A2 (en) 2006-09-28
JP2014055183A (ja) 2014-03-27
HK1112579A1 (en) 2008-09-12
EP2431042B1 (en) 2013-06-26
US20090325920A1 (en) 2009-12-31
CA2601715C (en) 2012-10-16
ES2428313T3 (es) 2013-11-07
PL1868614T3 (pl) 2013-01-31
PL2030622T3 (pl) 2011-07-29
AU2006226774B2 (en) 2010-12-02
JP2011225629A (ja) 2011-11-10
US20090221544A1 (en) 2009-09-03
EP1871382B1 (en) 2011-08-17
PT2030622E (pt) 2011-06-02
EP2030622B1 (en) 2011-02-23
HRP20110198T1 (hr) 2011-04-30
DK2030622T3 (da) 2011-05-02
ATE520404T1 (de) 2011-09-15
DK1868614T3 (da) 2012-11-12
CY1113253T1 (el) 2016-04-13
JP5496407B2 (ja) 2014-05-21
CA2602950A1 (en) 2006-09-28
RS52471B (en) 2013-02-28
AU2006226774A1 (en) 2006-09-28
AU2006226811B2 (en) 2010-11-25
EP1868614A2 (en) 2007-12-26
US20120245133A1 (en) 2012-09-27
EP2030622A1 (en) 2009-03-04
HK1112581A1 (en) 2008-09-12
ATE499104T1 (de) 2011-03-15
WO2006102596A2 (en) 2006-09-28
CA2602950C (en) 2012-10-30
EP2494976A1 (en) 2012-09-05
PT1868614E (pt) 2012-11-23
EP1871382A2 (en) 2008-01-02
EP2431042A1 (en) 2012-03-21
US8614203B2 (en) 2013-12-24
JP2013234191A (ja) 2013-11-21
HRP20120688T1 (hr) 2012-09-30
HK1128242A1 (en) 2009-10-23
JP2008534515A (ja) 2008-08-28
WO2006102644A3 (en) 2007-03-01

Similar Documents

Publication Publication Date Title
DE602006020353D1 (de) Progesterone Dosierungsanweisung in der Behandlung einer traumatischen Verletzung des Gehirns
PH12019502254A1 (en) Methods and systems for modulating stimuli to the brain with biosensors
WO2008039898A3 (en) Methods for the treatment of a traumatic central nervous system injury
EA201000603A1 (ru) ПРИМЕНЕНИЕ АНТИТЕЛ К TrkB ДЛЯ ЛЕЧЕНИЯ РЕСПИРАТОРНЫХ НАРУШЕНИЙ
MX2023001527A (es) Compuestos con actividad inductora de ferroptosis y metodos de uso de estos.
WO2012106444A3 (en) Methods, devices and systems for treating insomnia by inducing frontal cerebral hypothermia
EA201590870A1 (ru) АМИНОЗАМЕЩЕННЫЕ ИМИДАЗО[1,2-a]ПИРИДИНКАРБОКСАМИДЫ И ИХ ПРИМЕНЕНИЕ
BR112013007681A2 (pt) uso terapêutico de um agonista trl e terapia de combinação
ATE427759T1 (de) Behandlung von fettsucht und verbundenen erkrankungen
WO2017190044A8 (en) Methods for detecting and treating pain using brain activity
WO2008033440A3 (en) Treatment of hyperproliferative diseases with anthraquinones
WO2004096216A3 (en) Use of a topical medicament comprising riluzole
EA201991650A1 (ru) Способы лечения неврологических расстройств
HK1095285A1 (en) Benzamidine derivatives for treatment and prevention of mucositis
RU2013122987A (ru) Способ лечения комбинированного радиационно-термического поражения
WO2017011356A3 (en) Mcj inhibitors for use in treating drug-induced diseases and conditions
MX2019001337A (es) Métodos para tratar y prevenir efectos secundarios por tratamiento de cáncer.
EP2566856A4 (en) COMPOUNDS AND METHODS FOR TREATING CEREBRAL DISORDERS
WO2014201084A3 (en) Piroxicam transdermal composition to treat plantar fasciitis
MX2015013137A (es) Compuestos novedosos de modulación del control de la respiración, y sus métodos de uso.
ATE510530T1 (de) Verfahren zur verhinderung und/oder behandlung von altersflecken
WO2011071981A3 (en) Anti-cytomegalovirus activity of artemisinin-derived dimers
MXPA05012696A (es) Formulaciones de agentes antiinflamatorios no esteroides para tratar angiogenesis ocular patologica.
WO2008128155A3 (en) SIRTUIN BASED METHODS AND COMPOSITIONS FOR TREATING β- CATENIN-RELATED CONDITIONS
WO2017197249A3 (en) METHODS OF TREATING HYPER-BILIRUBINEMIA USING STANNSOPORFIN AND PHOTOTHERAPY